| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Passage BIO, Inc. | Chief Financial Officer | Common Stock | 5,454 | $4,963 | $0.9100 | 21 May 2021 | Direct |
| Carisma Therapeutics Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 85,000 | 17 Jun 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CARM | Carisma Therapeutics Inc. | 17 Jun 2024 | 1 | $0 | 4 | Chief Financial Officer | 18 Jun 2024, 19:08 |
| CARM | Carisma Therapeutics Inc. | 31 Jan 2024 | 1 | $0 | 4 | Chief Financial Officer | 02 Feb 2024, 16:53 |
| CARM | Carisma Therapeutics Inc. | 06 Jun 2023 | 1 | $0 | 4 | Chief Financial Officer | 08 Jun 2023, 18:18 |
| CARM | Carisma Therapeutics Inc. | 07 Mar 2023 | 1 | $0 | 4 | Chief Financial Officer | 09 Mar 2023, 20:26 |
| CARM | Carisma Therapeutics Inc. | 07 Mar 2023 | 0 | $0 | 3 | Chief Financial Officer | 09 Mar 2023, 20:13 |
| PASG | Passage BIO, Inc. | 21 May 2021 | 1 | +$30,000 | 4 | Chief Financial Officer | 21 May 2021, 18:09 |